CNSDose
CNSDose provides gene testing service and guides for the proper antidepressant.
Raised 1M SEED on July 13, 2016
About
CNSDose develops a genomic test to inform antidepressant selection, running clinical validation and preparing U.S. trial launch while building commercialization pathways from its Melbourne base.
Mission
CNSDose is building a genomic test intended to tailor antidepressant prescriptions and reduce trial-and-error prescribing. The concept was developed over nearly a decade by registered psychiatrist and founder Ajeet Singh. The company recently added former federal trade minister Andrew Robb as an advisor. CNSDose has closed a seed round of nearly $1 million from two anonymous individuals. The funding is being used to support a trial launch in the U.S. planned for October. The startup is based in Melbourne and is focused on clinical validation and commercialization of its test.
Quick Facts
Founded
2015
Funding
SEED
Industry
Biotechnology, Health Care, Health Diagnostics, Medical
Team Size
1-10
Headquarters
Melbourne, Victoria, Australia
Careers
View Careers Page
No open roles at this time.
Check their careers page for updates